SQZ Biotechnologies

📍 Watertown, United States🗓 Founded 2013👥 66 employees💰 Last funded May 2018
SQZ Biotechnologies is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies to benefit patients with cancer, autoimmune and infectious diseases. The company’s proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many patient cell types to engineer what we believe can be a broad range of potential therapeutics. Our goal is to create well-tolerated cell therapies that can provide therapeutic benefit for patients and improve the patient experience over existing cell therapy approaches. With accelerated production timelines under 24 hours and the opportunity to eliminate preconditioning and lengthy hospital stays, our approach could change the way people think about cell therapies. The company’s first therapeutic applications seek to generate target-specific immune responses, both in activation for the treatment of solid tumors and in immune tolerance for the treatment of unwanted immune reactions and autoimmune diseases.
3
Total investors
1
Early stage
1
Mid stage
0
Late stage
2013
Founded
Investor geography1 country
United States
3
Investor activity2014–2018 · investors recorded per year
201412016120181
Recent (last 2y)Earlier
Frequently asked questions
Who invested in SQZ Biotechnologies?
SQZ Biotechnologies has 3 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage.
When did SQZ Biotechnologies last raise funding?
The most recent investment in SQZ Biotechnologies recorded on gritt.io was in May 2018.
When was SQZ Biotechnologies founded?
SQZ Biotechnologies was founded in 2013.
What industry is SQZ Biotechnologies in?
SQZ Biotechnologies operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is SQZ Biotechnologies based?
SQZ Biotechnologies is headquartered in Watertown, United States.